Edward Messing

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. pmc Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression
    Timothy K Byler
    Department of Urology, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    BMC Urol 12:21. 2012
  2. pmc Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria
    Deep Trivedi
    Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
    BMC Urol 9:13. 2009
  3. pmc Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Elmwood Avenue, Rochester, New York, USA
    BMC Urol 8:7. 2008
  4. pmc Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator
    Hani H Rashid
    Department of Urology, University of Rochester, Rochester, New York, USA
    BMC Urol 4:3. 2004
  5. ncbi request reprint The timing of hormone therapy for men with asymptomatic advanced prostate cancer
    Edward Messing
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 21:245-54. 2003
  6. ncbi request reprint Markers of detection
    Edward Messing
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 25:344-7. 2007
  7. ncbi request reprint Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
    Edward M Messing
    Department of Urology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Lancet Oncol 7:472-9. 2006
  8. ncbi request reprint Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial
    Edward M Messing
    University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 21:1214-22. 2003
  9. doi request reprint Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease
    Edward M Messing
    Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 27:2443-9. 2009
  10. ncbi request reprint Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States
    Edward M Messing
    Department of Urology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Urol 174:1238-41. 2005

Detail Information

Publications81

  1. pmc Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression
    Timothy K Byler
    Department of Urology, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    BMC Urol 12:21. 2012
    ..We speculated that inhibition of angiogenesis by valproate might be mediated by this anti-angiogenic protein...
  2. pmc Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria
    Deep Trivedi
    Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
    BMC Urol 9:13. 2009
    ....
  3. pmc Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Elmwood Avenue, Rochester, New York, USA
    BMC Urol 8:7. 2008
    ..Furthermore, because BC growth in UPII-SV40T mice is exophytic, we speculated BC growth was dependent on angiogenesis and angiogenesis was, in turn, androgen responsive...
  4. pmc Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator
    Hani H Rashid
    Department of Urology, University of Rochester, Rochester, New York, USA
    BMC Urol 4:3. 2004
    ..This study was performed to determine the effect of APF on the cell cycle of bladder epithelial cells so as to better understand its antiproliferative activity...
  5. ncbi request reprint The timing of hormone therapy for men with asymptomatic advanced prostate cancer
    Edward Messing
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 21:245-54. 2003
    ..It is recommended that after an assessment of their disease risk, patients should be informed about the benefits and side effects of all potential treatment options and allowed to make an informed choice about their treatment...
  6. ncbi request reprint Markers of detection
    Edward Messing
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 25:344-7. 2007
    ..However, markers may be useful for directing which patients age <or=40 with asymptomatic microhematuria without histories of smoking, particularly women, require cystoscopic evaluation...
  7. ncbi request reprint Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
    Edward M Messing
    Department of Urology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Lancet Oncol 7:472-9. 2006
    ....
  8. ncbi request reprint Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial
    Edward M Messing
    University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 21:1214-22. 2003
    ..To evaluate the role of adjuvant interferon alfa after complete resection of locally extensive renal cell carcinoma...
  9. doi request reprint Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease
    Edward M Messing
    Department of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Oncol 27:2443-9. 2009
    ..Our goal was to determine whether presenting grade and stage of bladder cancer (BC), which directly affect disease-specific survival, also influence time to and cause of non-BC deaths...
  10. ncbi request reprint Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States
    Edward M Messing
    Department of Urology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Urol 174:1238-41. 2005
    ..We assessed the performance of the ImmunoCyt immunocytochemical test for detecting bladder cancer recurrence in patients with prior superficial bladder cancers compared with cystoscopic and histological findings...
  11. ncbi request reprint Long-term outcome of hematuria home screening for bladder cancer in men
    Edward M Messing
    Department of Urology, University of Rochester, Rochester, New York 14642, USA
    Cancer 107:2173-9. 2006
    ....
  12. ncbi request reprint Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer
    Edward Messing
    University of Rochester, Rochester, New York 14642, USA
    J Urol 176:500-4. 2006
    ..Ornithine decarboxylase catalyzes the rate limiting step in polyamine synthesis and its activity can be inhibited by difluoromethylornithine, which has been shown in preclinical studies, to prevent bladder cancer...
  13. ncbi request reprint Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy
    Edward M Messing
    Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    Urol Clin North Am 30:687-702, viii. 2003
    ..This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies...
  14. doi request reprint Non-bladder cancer mortality in patients with urothelial cancer of the bladder
    Emil Scosyrev
    Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Urol Oncol 31:656-63. 2013
    ..Because bladder cancer (BC) patients often have comorbidities that adversely affect their health, we wanted to determine whether grade and stage of BC at diagnosis are associated with the hazard of death from causes other than BC...
  15. ncbi request reprint Robot-assisted prostate brachytherapy
    Yan Yu
    Department of Radiation Oncology, University of Rochester, Rochester, NY 14642, USA
    Med Image Comput Comput Assist Interv 9:41-9. 2006
    ..Preliminary experimental results reveal that the prototype system is quite accurate (sub-millimeter) in placing brachytherapy needles...
  16. ncbi request reprint Hybrid dosimetry: feasibility of mixing angulated and parallel needles in planning prostate brachytherapy
    Lei Fu
    Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York 14642, USA
    Med Phys 33:1192-8. 2006
    ..When close to the breakdown point, the dosimetry outcomes worsen drastically. Therefore, for moderate PAI the hybrid dosimetry is feasible...
  17. ncbi request reprint Vivo motion and force measurement of surgical needle intervention during prostate brachytherapy
    Tarun Podder
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Med Phys 33:2915-22. 2006
    ..The knowledge gleaned from this study promises to be useful for not only designing mechanical/robotic systems but also developing a predictive deformation model of the prostate and real-time adaptive controlling of the needle...
  18. doi request reprint Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging
    Scott Tobis
    Department of Urology, University of Rochester Medical Center, Rochester, New York, USA
    J Endourol 26:797-802. 2012
    ..The feasibility of a novel intraoperative imaging technique to differentiate tumor from surrounding parenchyma during laparoscopic and robot-assisted partial nephrectomy was evaluated...
  19. ncbi request reprint Surveillance for recurrent bladder cancer using a point-of-care proteomic assay
    H Barton Grossman
    Department of Urology, M D Anderson Cancer Center, Houston, Tex 77030, USA
    JAMA 295:299-305. 2006
    ..At least 50% of patients with a history of bladder cancer have recurrences, so rigorous surveillance is necessary. Cystoscopy is standard but can fail to detect some bladder cancers, so a urine test is frequently part of the evaluation...
  20. doi request reprint Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice
    Emil Scosyrev
    Department of Community, Preventive Medicine, University of Rochester, Rochester, NY, USA
    Urology 76:908-13; discussion 914. 2010
    ....
  21. doi request reprint Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies
    Emil Scosyrev
    Department of Urology, University of Rochester Medical Center, Rochester, NY, USA
    BJU Int 111:E71-7. 2013
    ..However, there was considerable disagreement between individual studies in reported findings and conclusions...
  22. doi request reprint Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection
    Yair Lotan
    Department of Urology, University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA
    BJU Int 101:1362-7. 2008
    ..Newton, MA, USA) for the detection of bladder cancer, as this is a point-of-care assay that measures NMPs in voided urine...
  23. ncbi request reprint Bouquet brachytherapy: feasibility and optimization of conically spaced implants
    Lei Fu
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642 8647, USA
    Brachytherapy 4:59-63. 2005
    ..To examine the dosimetric feasibility of a conical implantation approach to robotic-assisted prostate brachytherapy...
  24. doi request reprint Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview
    Emil Scosyrev
    Department of Community and Preventive Medicine, University of Rochester, Rochester, NY 14642, USA
    Urol Oncol 30:126-32. 2012
    ....
  25. doi request reprint The burden of bladder cancer in men and women: analysis of the years of life lost
    Emil Scosyrev
    Department of Urology, University of Rochester Medical Center, Rochester, NY, USA
    BJU Int 109:57-62. 2012
    ..To estimate the average loss in life expectancy (LE) due to bladder cancer (BC) in men and women in the USA...
  26. ncbi request reprint Is there a favorable subset of patients with prostate cancer who develop oligometastases?
    Deepinder Singh
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642 8647, USA
    Int J Radiat Oncol Biol Phys 58:3-10. 2004
    ....
  27. ncbi request reprint Androgen deprivation therapy for prostate cancer: current status and future prospects
    Hiroshi Miyamoto
    George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Prostate 61:332-53. 2004
    ..In order to improve overall survival, novel treatment strategies that prolong the androgen-dependent state and that are useful for androgen-independent disease based on specific molecular mechanisms need to be identified...
  28. doi request reprint Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system
    Emil Scosyrev
    Department of Urology, University of Rochester Medical Center, NY, USA
    BJU Int 110:1485-90. 2012
    ..To examine the frequency of PSA testing in men aged ≥75 years before and after the 2008 US Preventive Services Task Force (USPSTF) recommendation to stop prostate-specific antigen (PSA) screening at age 75...
  29. doi request reprint Near infrared fluorescence imaging after intravenous indocyanine green: initial clinical experience with open partial nephrectomy for renal cortical tumors
    Scott Tobis
    Department of Urology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Urology 79:958-64. 2012
    ....
  30. doi request reprint A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D
    Huei Ju Ting
    Department of Urology, University of Rochester, Rochester, New York, USA
    Cancer Res 72:958-68. 2012
    ..Together, our findings identify a novel vitamin D-mediated chemopreventive mechanism involving a positive feedback loop between the DNA repair proteins ATM and VDR...
  31. doi request reprint Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?
    Emil Scosyrev
    Department of Community and Preventive Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Urology 73:822-7. 2009
    ..To determine whether the survival of patients with squamous cell carcinoma (SCC) is different from that of patients with urothelial carcinoma, after adjusting for stage, grade, demographic factors, and the initial treatment...
  32. ncbi request reprint Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    JAMA 296:2329-35. 2006
    ..However, the optimal management of these patients after radical prostatectomy is unknown...
  33. ncbi request reprint Long-term outcome of home dipstick testing for hematuria
    Ralph Madeb
    Department of Urology, Strong Memorial Hospital, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    World J Urol 26:19-24. 2008
    ..8 years. The lower overall mortality in screenees with BC was primarily because of the reduced mortality from BC in that group. Screening had effected a shift of the high grade tumors to earlier (more superficial) stages at diagnosis...
  34. ncbi request reprint Chemoprevention of bladder cancer
    Dragan J Golijanin
    Urology Department, University of Rochester Medical Center, 601 Elmwood Avenue, P O Box 656, Rochester, NY 14642, USA
    World J Urol 24:445-72. 2006
  35. ncbi request reprint Androgen deprivation therapy for prostate cancer
    Eric A Singer
    Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Expert Opin Pharmacother 9:211-28. 2008
    ....
  36. doi request reprint Quantitative characterization of viscoelastic properties of human prostate correlated with histology
    Man Zhang
    Department of Biomedical Engineering, University of Rochester, Rochester, NY 14627, USA
    Ultrasound Med Biol 34:1033-42. 2008
    ..01). This study contributes to the current limited knowledge on the viscoelastic properties of the human prostate, and the inherent elastic contrast produced by cancer...
  37. pmc Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors
    Ralph Madeb
    Department of Urology, University of Rochester School of Medicine, Rochester, New York, USA
    Cancer 115:2660-70. 2009
    ..The authors sought to determine whether US urologists have adopted this practice, and its potential effect on costs of bladder cancer (BC) care...
  38. ncbi request reprint Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate
    Ronald W Wood
    Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642 8668, USA
    Urology 67:1324-8. 2006
    ..Spontaneous death from urinary outlet obstruction occurs in the TRAMP mouse...
  39. ncbi request reprint CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes
    Ronald H Gottlieb
    Dept of Radiology, Univ of Rochester Medical Ctr, NY 14642, USA
    Radiology 225:441-9. 2002
    ....
  40. ncbi request reprint Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, NY 14642, USA
    Nat Clin Pract Oncol 2:236-7. 2005
  41. ncbi request reprint 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer
    Jong Wei Hsu
    Department of Urology, University of Rochester, Rochester, New York, USA
    Oncotarget 4:2397-406. 2013
    ..These data demonstrate a novel mechanism by which 1,25-VD promotes BCG-mediated anti-BCa pathways and provides a platform for improving BCG efficacy with combination of 1,25-VD...
  42. ncbi request reprint Detection of bladder cancer using a point-of-care proteomic assay
    H Barton Grossman
    Department of Urology, M D Anderson Cancer Center, Houston, Tex 77030, USA
    JAMA 293:810-6. 2005
    ..Urine tests are frequently part of an evaluation, but have either been nonspecific for cancer or required specialized analysis at a laboratory...
  43. doi request reprint Female bladder cancer: incidence, treatment, and outcome
    Emil Scosyrev
    Department of Community and Preventive Medicine, University of Rochester, Rochester, New York, USA
    Curr Opin Urol 20:404-8. 2010
    ..In this review, we describe our current understanding of the relationship between sex and bladder cancer incidence and outcomes and discuss the most recent developments in this area of research...
  44. doi request reprint Sex and racial differences in bladder cancer presentation and mortality in the US
    Emil Scosyrev
    Department of Community and Preventive Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 115:68-74. 2009
    ....
  45. ncbi request reprint Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
    Vinata B Lokeshwar
    Department of Urology, University of Miami, Miami, Florida 33101, USA
    Urology 66:35-63. 2005
    ..Therefore, use of bladder tumor markers in the management of patients with bladder cancer will require the willingness of both urologists and clinicians to accept them...
  46. ncbi request reprint Transrectal sonography in prostate evaluation
    Judd Boczko
    Department of Urology, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    Radiol Clin North Am 44:679-87, viii. 2006
    ..This article review the indications and principles of TRUS of the prostate, the technique of TRUS, and controversies pertaining to prostate core biopsy...
  47. ncbi request reprint Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Eric A Singer
    Department of Urology, University of Rochester Medical Center, Rochester, New York USA
    Can J Urol 15:4381-7. 2008
    ..Additionally, strategies for addressing each of these escape mechanisms, which may be able to prolong responsiveness to ADT, will be discussed...
  48. ncbi request reprint Early versus late hormonal therapy for prostate cancer
    Hiroshi Miyamoto
    Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    Curr Urol Rep 5:188-96. 2004
    ....
  49. doi request reprint Controversies surrounding lymph node dissection for prostate cancer
    Ganesh S Palapattu
    Department of Urology, The Methodist Hospital, 6560 Fannin, Suite 2100, Houston, TX 77030, USA
    Urol Clin North Am 37:57-65, Table of Contents. 2010
    ..The lack of robust randomized clinical trials in the literature necessitates a careful analysis of retrospective and case series data...
  50. ncbi request reprint Timing hormonal therapy in prostate cancer
    Annette E Sessions
    Department of Urology, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Urol Clin North Am 29:223-7, xi. 2002
    ..Studies have pointed to the benefits of initiating androgen ablation therapy earlier in the treatment of prostate cancer; the greatest benefits of anti-androgen therapy may be gained when only tiny amounts of prostate cancer are present...
  51. ncbi request reprint A randomized trial of 2% lidocaine gel versus plain lubricating gel for minimizing pain in men undergoing flexible cystoscopy
    Marianne Borch
    Urology Outpatient Clinic, University of Rochester Medical Center, Rochester, NY, USA
    Urol Nurs 33:187-93. 2013
    ..Compared with the plain gel, use of lidocaine resulted in significantly less pain during the procedure...
  52. doi request reprint Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer
    Manish Kohli
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Cancer Biomark 7:101-8. 2010
    ..An association of a single nucleotide polymorphism (SNP) of the KLK2 gene (rs198977; c.748C>T; R250W) with risk for developing prostate cancer has been observed. We evaluated the role of R250W SNP for prognosis in prostate cancer...
  53. ncbi request reprint Grade progression and regression in recurrent urothelial cancer
    Ali Borhan
    Department of Urology, University of Rochester, Rochester, New York 14642, USA
    J Urol 169:2106-9. 2003
    ..We determined how often grade progression and regression occur and whether abnormalities in p53 protein expression in original tumors are preserved in recurrences...
  54. ncbi request reprint Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors
    Terrence L Fisher
    Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester Cancer Center, 575 Elmwood Avenue, Rochester, NY 14642, USA
    Prostate 51:153-65. 2002
    ..In order to further elucidate the possible roles of hK2 in prostate cancer, we have generated a panel of hK2-specific, non-PSA cross-reactive monoclonal antibodies...
  55. ncbi request reprint Uroflow in murine urethritis
    Yuk Yuen Max Leung
    Department of Urology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642 8668, USA
    Urology 64:378-82. 2004
    ..This could be useful for the study of bladder outlet obstruction, as well as processes affecting detrusor function in the awake animal. Genetically engineered mice can improve our understanding of a variety of human bladder diseases...
  56. doi request reprint Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin
    Jason R Gee
    Department of Urology, School of Medicine and Public Health, University of Wisconsin Madison, Madison, WI 53792, USA
    BJU Int 103:736-9. 2009
    ....
  57. ncbi request reprint Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness
    Huei Ju Ting
    Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA
    Mol Cancer Res 5:967-80. 2007
    ....
  58. pmc Androgen receptor is a tumor suppressor and proliferator in prostate cancer
    Yuanjie Niu
    George Whipple Lab for Cancer Research, Department of Pathology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Proc Natl Acad Sci U S A 105:12182-7. 2008
    ..Collectively, our understanding of these opposing roles of prostatic AR may revolutionize the way we combat prostate cancer, and allow the development of new and better therapies by targeting only the proliferative role of AR...
  59. doi request reprint Decreased bladder cancer growth in parous mice
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Urology 72:470-3. 2008
    ..To investigate the association between parity and exophytic bladder cancer growth in the UPII-SV40T transgenic mouse model of bladder cancer...
  60. pmc A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
    Edward Messing
    University of Rochester Medical Center, Rochester, New York, USA
    Cancer Prev Res (Phila) 5:621-30. 2012
    ..Genistein displayed a possible bimodal effect (more effective at the lower dose) on bladder cancer tissue EGFR phosphorylation that should be evaluated further, possibly in combination with other agents...
  61. doi request reprint Lost and now found: retained straight catheter for 20 years
    Emma Ester Bendaña
    University of Rochester Medical Center, Rochester, NY 14642, USA
    Urology 77:73-4. 2011
    ..A Foley catheter was inserted easily into the urethra for drainage. At last follow-up, 7 weeks after surgery, the patient was voiding successfully without any difficulties...
  62. ncbi request reprint Automatic localization of implanted seeds from post-implant CT images
    Haisong Liu
    Department of Radiation Oncology, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Phys Med Biol 48:1191-203. 2003
    ..It is reliable and convenient for localizing implanted seeds on CT and can be used to assist post-implant dosimetry for prostate brachytherapy...
  63. doi request reprint Down-regulation of NF-kappaB signals is involved in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness
    Bo Ying Bao
    Department of Urology and Pathology and Laboratory Medicine, Rochester, NY 14642, USA
    J Steroid Biochem Mol Biol 120:11-21. 2010
    ..Together, we conclude that NF-kappaB signaling is critical for vitamin D sensitivity, and dysregulation of this pathway would result in vitamin D resistance and disease progression...
  64. doi request reprint Long-term outcome of patients with a negative work-up for asymptomatic microhematuria
    Ralph Madeb
    Department of Urology, University of Rochester School of Medicine, Rochester, New York, USA
    Urology 75:20-5. 2010
    ....
  65. ncbi request reprint Promotion of bladder cancer development and progression by androgen receptor signals
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, 601 Elmwood Ave, Box 626, Rochester, NY 14642, USA
    J Natl Cancer Inst 99:558-68. 2007
    ..Unlike prostate cancer, human bladder cancer is not generally considered to be dependent on hormone activity. We investigated the possible involvement of androgens and the androgen receptor (AR) in bladder cancer...
  66. ncbi request reprint Prostate cancer: three-dimensional sonoelastography for in vitro detection
    Lawrence S Taylor
    Department of Biomedical Engineering, University of Rochester, 240 Hutchison Rd, Rm 205, Rochester, NY 14627 0126, USA
    Radiology 237:981-5. 2005
    ..To prospectively evaluate the accuracy of three-dimensional (3D) sonoelastographic imaging, relative to that of gray-scale ultrasonography (US), in the in vitro detection of prostate cancer...
  67. ncbi request reprint Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells
    Yi Fen Lee
    George Whipple Laboratory for Cancer Research, Department of Pathology, and the Cancer Center, University of Rochester Medical Center, New York 14642, USA
    Cancer Res 62:6039-44. 2002
    ..This raises a concern for using HF in the complete-androgen-ablation therapy in prostate cancer treatment and provides a possible pathway that might contribute to the HF withdrawal syndrome...
  68. ncbi request reprint Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Mol Carcinog 44:1-10. 2005
    ..We hypothesize that androgen deprivation, in combination with inhibition of the Akt, COX-2, and MMP-9 pathways, delays the androgen-independent transition and has more beneficial effects than hormonal therapy alone...
  69. ncbi request reprint Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas
    Xi Na
    Department of Urology, University of Rochester Medical Center, New York 14642, USA
    J Urol 170:588-92. 2003
    ..However, quantitative analyses of VEGF production and its correlation with VHL mutations and HIF-1 alpha expression in authentic tissues from patients with RCC are lacking...
  70. pmc Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein
    Xi Na
    Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    EMBO J 22:4249-59. 2003
    ..Together, our results suggest that hsRPB7 is a downstream target of the VHL ubiquitylating complex and pVHL may regulate angiogenesis by targeting hsRPB7 for degradation via the ubiquitylation pathway and preventing VEGF expression...
  71. ncbi request reprint Early detection and measurement of urothelial tumors in mice
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Urology 67:1309-14. 2006
    ..To establish reliable noninvasive in vivo methods to detect, measure, and monitor experimentally induced urothelial tumors in mice...
  72. pmc Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells
    Yu Zhang
    Department of Urology, University of Rochester, Rochester, NY 14642, USA
    Proc Natl Acad Sci U S A 99:7408-13. 2002
    ..This previously undescribed mechanism may explain how VES inhibits the growth of prostate cancer cells and help us to establish new therapeutic concepts for the prevention and treatment of prostate cancer...
  73. doi request reprint Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice
    Ming Chen
    Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, New York 14642, USA
    Endocrinology 150:251-9. 2009
    ....
  74. ncbi request reprint Current state of screening for bladder cancer
    Ralph Madeb
    University of Rochester School of Medicine, Department of Urology, Rochester, NY, USA
    Expert Rev Anticancer Ther 7:981-7. 2007
    ..This special report reviews the current state of bladder cancer screening in the USA...
  75. ncbi request reprint Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway
    Jing Ni
    Department of Urology, University of Rochester, Rochester, New York, USA
    Cancer Res 65:9807-16. 2005
    ..Therefore, TAP may represent a new prognostic marker for prostate cancer progression...
  76. ncbi request reprint Gender, racial and age differences in bladder cancer incidence and mortality
    Ralph Madeb
    Department of Urology, Strong Memorial Hospital University of Rochester Medical Center, NY, USA
    Urol Oncol 22:86-92. 2004
    ..In this manuscript we review the current literature and epidemiological studies on the affects of gender, race and age on incidence and mortality of bladder cancer...
  77. ncbi request reprint A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis
    Robert Mayer
    University of Rochester, Rochester, New York, USA
    J Urol 173:1186-91. 2005
    ..We compared intravesical bacillus Calmette-Guerin (BCG) to placebo instillations in patients with treatment refractory interstitial cystitis (IC)...
  78. ncbi request reprint Continuous bladder infusion methods for studying voiding function in the ambulatory mouse
    Annette Sessions
    Department of Urology, University of Rochester School of Medicine, Rochester, New York 14642 8668, USA
    Urology 60:707-13. 2002
    ..To develop a method for chronic cannulation of the mouse bladder that would enable repeated intravesical drug delivery and measurement of voiding patterns in unrestrained mice under controlled infusion conditions...
  79. ncbi request reprint Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
    Edward M Messing
    J Urol 170:1955; author reply 1955-6. 2003
  80. ncbi request reprint Node positive renal cell cancer. Who can be helped?
    Edward M Messing
    Eur Urol 51:1477-8. 2007
  81. ncbi request reprint Bladder tumor markers
    Edward M Messing
    J Urol 175:1195-6. 2006